Entecavir

Treatment of Chronic Hepatitis B

Entecavir is primarily prescribed to manage long-term hepatitis B virus (HBV) infection. It is used in patients who show signs that the virus is actively multiplying and causing liver damage. This includes:

• Adults with chronic HBV.
• Children and adolescents from 2 to 17 years of age.

The medication is typically used when there is evidence of persistent inflammation of the liver or when a liver biopsy shows active disease. By decreasing the amount of the virus in the body, entecavir helps reduce the risk of liver damage associated with the infection.

Important Considerations

While entecavir helps manage the infection, it is important to understand its limitations:

• It is not a cure for hepatitis B.
• It does not prevent the transmission of hepatitis B to others through blood or sexual contact.
• It does not lower the risk of developing liver cancer or cirrhosis, although it helps control the virus that contributes to these conditions.

How Entecavir Works

Entecavir belongs to a class of drugs known as nucleoside analogues. It is specifically designed to treat chronic hepatitis B virus (HBV) infections by interfering with the virus's ability to multiply.

Blocking Viral Replication

To reproduce and spread, the hepatitis B virus must create copies of its own genetic material (DNA). Entecavir works by blocking a specific enzyme called HBV polymerase, which the virus requires to build new DNA strands. By inhibiting this enzyme, the medication prevents the virus from making copies of itself.

Reducing Viral Load

When the virus cannot replicate effectively, the amount of hepatitis B virus in the blood—often called the viral load—decreases. Lowering the viral load helps to limit the damage the virus can cause to the liver over time.

Important Considerations

While entecavir is effective at controlling the virus, it is important to understand its limitations:

• Not a cure: Entecavir does not cure hepatitis B or completely remove the virus from the body.
• Transmission: The medication does not prevent the spread of hepatitis B to other people through blood or sexual contact.
• Long-term health: It may not prevent long-term complications of hepatitis B, such as liver cirrhosis or liver cancer.

Common Side Effects

The most common side effects reported with entecavir include:

• Headache
• Tiredness or fatigue
• Dizziness
• Nausea

Serious Side Effects

Entecavir can cause lactic acidosis, a serious medical emergency where acid builds up in the blood. Seek immediate medical attention if you experience:

• Feeling very weak or tired
• Unusual muscle pain
• Stomach pain with nausea and vomiting
• Feeling cold, especially in the arms and legs
• Dizziness or lightheadedness
• Fast or irregular heartbeat

This medication may also cause severe liver problems. Contact your healthcare provider right away if you notice symptoms such as:

• Yellowing of the skin or the whites of the eyes (jaundice)
• Dark-colored urine
• Light-colored bowel movements
• Loss of appetite for several days or longer
• Pain in the upper right side of the stomach area

Serious allergic reactions are rare but require emergency care. Symptoms include a rash, hives, or swelling of the face, lips, tongue, or throat.

Hepatitis B Exacerbation

Severe, acute worsening of hepatitis B has been reported in patients who stop taking entecavir. Liver function should be monitored closely with both clinical and laboratory follow-up for several months after treatment is discontinued. In some instances, resuming anti-hepatitis B therapy may be required.

Lactic Acidosis and Severe Hepatomegaly

Lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty liver (steatosis), including fatal cases, have been reported with the use of nucleoside analogues like entecavir. Emergency medical attention may be necessary if symptoms of lactic acidosis occur, such as:

• Feeling very weak or tired
• Unusual muscle pain
• Trouble breathing
• Stomach pain with nausea and vomiting
• Feeling cold, especially in the arms and legs
• Feeling dizzy or lightheaded
• Fast or irregular heartbeat

HIV Co-infection

In patients with unrecognized or untreated HIV infection, entecavir may lead to the development of HIV resistance to certain medications. Testing for HIV infection is recommended before starting treatment for hepatitis B with entecavir.

Kidney Impairment

Dose adjustments are recommended for patients with impaired kidney function because the medication is primarily cleared by the kidneys. Healthcare providers typically assess kidney function before and during treatment to determine the appropriate dosage.

Liver Transplant Recipients

The safety and effectiveness of entecavir in liver transplant recipients are not fully established. If treatment is necessary for these patients, kidney function is usually monitored closely, particularly if they are taking immunosuppressant medications that may affect the kidneys, such as cyclosporine or tacrolimus.

Pregnancy

It is not known whether entecavir will harm an unborn baby. There is limited research on the effects of this medication in pregnant individuals. If you are pregnant or planning to become pregnant, it is important to inform your healthcare provider. They can help weigh the risks of the medication against the risks of untreated hepatitis B during pregnancy.

Breastfeeding

It is currently unknown if entecavir passes into human breast milk or if it could cause adverse effects in a nursing infant. Because of the potential for serious reactions, healthcare providers generally advise against breastfeeding while taking this medication. Additionally, individuals with hepatitis B should discuss the risk of transmitting the virus to their baby with their doctor.

Available Forms

Entecavir is provided in the following oral formulations:

• Oral Tablet
• Oral Solution

The oral solution is a liquid form of the medication. It is often used for patients who have difficulty swallowing tablets or when precise measurements are necessary.

FDA Approval and Indications

Entecavir was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection. It is indicated for use in adults and children at least 2 years of age who show signs of active viral replication and evidence of liver inflammation or damage.

Boxed Warnings

The FDA has issued several boxed warnings for entecavir, which represent the most serious safety alerts for prescription medications:

• Severe Acute Exacerbations of Hepatitis B: Discontinuing entecavir treatment may lead to a severe, acute worsening of hepatitis B. Patients who stop taking the medication must be monitored closely by a healthcare provider for several months to check liver function.
• HIV Resistance: In patients who have both HBV and an unrecognized or untreated HIV infection, entecavir may cause the HIV virus to develop resistance to certain antiviral treatments. It is generally not recommended for patients with HIV/HBV co-infection who are not also receiving highly active antiretroviral therapy (HAART).
• Lactic Acidosis and Liver Issues: There is a risk of lactic acidosis (a dangerous buildup of acid in the blood) and severe hepatomegaly with steatosis (an enlarged fatty liver). These conditions can be life-threatening and have been reported with the use of medications in the same class as entecavir.

Regulatory Status

Entecavir is a prescription-only medication. It is not approved for the treatment of HIV infection. Because of the risk of drug resistance, healthcare providers typically screen patients for HIV infection before starting entecavir therapy.

Generic vs. Brand Name

Entecavir is available in both generic and brand-name (Baraclude) forms. Generic drugs are usually less expensive than their brand-name counterparts while providing the same therapeutic benefits. Choosing the generic version is a common way to reduce the cost of treatment for chronic hepatitis B.

Insurance Coverage

Most prescription insurance plans, including Medicare Part D and Medicaid, provide coverage for generic entecavir. The specific out-of-pocket cost, such as a copayment or coinsurance, depends on the individual's insurance plan and the drug's placement on the plan's formulary.

Formulation and Pharmacy Variations

The cost of entecavir can vary based on the formulation prescribed, such as oral tablets or an oral solution. Additionally, prices may differ between retail pharmacies. Patients may find different pricing at local drugstores compared to mail-order pharmacy services.

Financial Assistance Programs

For patients who are uninsured or underinsured, financial assistance may be available. Some pharmaceutical manufacturers offer patient assistance programs or savings cards that can help lower the cost of the brand-name medication for eligible individuals.